DNA sequencing market seen reaching $69.05B by 2035

The global DNA sequencing market is projected to grow from $13.65 billion in 2025 to $69.05 billion by 2035, fueled by falling sequencing costs, broader reimbursement, and national genomics programs. Clinical diagnostics is now overtaking research as the main demand driver, with oncology and hospital testing expected to keep expanding.

Why it matters: - DNA sequencing is moving from a research-heavy category into routine clinical infrastructure. - Lower costs and wider reimbursement are making sequencing more accessible for hospitals, labs, and national health systems. - The shift is expanding recurring demand for instruments, consumables, and interpretation services.

What happened: - Market Research Future projects the global DNA sequencing market will rise from $13.65 billion in 2025 to $69.05 billion by 2035. - The forecast implies a 17.6% compound annual growth rate from 2026 to 2035. - The market's growth is tied to declining cost per genome, reimbursement expansion, and national precision-medicine programs. - The release included sample, customization, and report links for the market study: Request a free sample, request customization, and read the detailed report.

The details: - Sequencing costs have fallen from about $1,000 per genome in 2019 to under $200 on high-output configurations by 2024. - The U.S. Centers for Medicare & Medicaid Services established a reimbursable pathway for next-generation sequencing in advanced cancer, with estimated annual U.S. testing spend of $1.9 billion by 2025. - Genomics England's GBP 105 million Newborn Genomes Programme and India's Genome India initiative are helping build permanent testing infrastructure. - WHO data show more than 90 countries had national sequencing nodes by 2024 under the Global Genomic Surveillance Strategy. - Clinical diagnostics generated $6.47 billion in 2025 and became the larger demand center than research for the first time. - Oncology is the largest sub-application and is growing at a 17.8% CAGR. - Consumables held the largest product share at 54.2% in 2025. - Instruments accounted for 30.6% of the market in 2025. - Services are the fastest-growing product category, with a 16.8% CAGR through 2035. - Next-generation sequencing held 76.1% of the technology market in 2025. - Nanopore sequencing is the fastest-growing technology, with a 25.9% CAGR over 2026–2035. - Sanger sequencing retained a 9.8% share in 2025 as a confirmatory method. - Sequencing was the largest workflow step with a 42.2% share in 2025. - Data analysis and storage is the fastest-growing workflow step, with a 20.7% CAGR. - Sample preparation generated $3.73 billion in 2025. - Academic institutions held the largest end-user share at 37.4% in 2025. - Hospitals and clinical laboratories are the fastest-growing end-user group, with a 15.7% CAGR. - Pharmaceutical and biotechnology companies contributed $3.40 billion in 2025.

Between the lines: - The market is being reshaped by reimbursement, not just technology improvement. - As sequencing becomes billable, laboratories can justify purchases on clinical throughput rather than research budgets. - National genomics programs reduce adoption risk by standardizing consent, storage, and interpretation frameworks. - The economics favor suppliers with recurring consumables and software revenue, not only hardware sales. - The release says the industry is moderately concentrated, with the top five suppliers holding about 61% to 66% of global revenue.

What's next: - North America is expected to remain the largest regional market, with 41.6% of global revenue in 2025 and about $5.68 billion in revenue. - Asia-Pacific is projected to post the fastest regional growth at a 20.3% CAGR through 2035. - Europe should keep expanding through national programs and insurer reimbursement. - Sequencing-as-a-service, managed informatics, and point-of-care sequencing are likely to gain share as customers seek lower upfront costs and faster turnaround. - By 2035, clinical diagnostics is expected to remain the main demand driver, while interpretation services capture more of the value chain.

The bottom line: - DNA sequencing is shifting into a scale business powered by clinical demand, recurring consumables, and national health-system adoption.